DrugMapper
Browse
Therapeutic Area
CANCER (51)
CARDIOVASCULAR (45)
DENTISTRY (2)
DERMATOLOGY (31)
DIABETES DRUGS & ENDOCRINOLOGY (61)
EMERGENCY MEDICINE (3)
ENT (5)
EYE (23)
GASTROINTESTINAL (29)
HEMATOLOGY (23)
MUSCULOSKELETAL (28)
NEUROLOGY DRUGS & NERVOUS SYSTEM (50)
PEDIATRICS (27)
PHARMACOLOGY (8)
PREGNANCY AND GYNECOLOGY (30)
RESPIRATORY (42)
RHEUMATOLOGY (19)
OTHER (1482)
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Primary Target
Target Level
Level 1
Level 2
Level 3
Level 4
Level 5
Level 6
Active Pharmaceutical Ingredients (APIs)
Small Molecules
ProDrugs
Antibodies
CNS drugs
Metabolites
Search
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Target Sequence
Chemical Structure
Physicochemical Properties
Analyze
Networks
Chemical Similarity
Scaffold Similarity
KNIME workflow
Downloads
Web services
Bulk Downloads
About
DrugMapper FAQs
Data Sources
Contact Us
Display Options:
Drug type
Therapeutic Area
Route of administration
Mechanism of Action
Indication
Status
Total:
6532
TUCATINIB
2020
Small molecule
Approved
Unknown
Unknown
Carcinoma, Non-Small-Cell Lung; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Liver Diseases; Hemangiosarcoma; Brain Neoplasms; Breast Neoplasms; Neoplasms
Receptor protein-tyrosine kinase erbB-2 inhibitor
TUCATINIB
×
Maximum Phase:
4
First Approval:
2020
UNII:
234248D0HH
Molecule Type:
Small molecule
Molecular Formula:
C26H24N8O2
Molecular Weight:
480.53
AlogP:
5.09
PSA:
110.85
HBD:
2.0
HBA:
#RotB:
5.0
Source:
PRALSETINIB
2020
Small molecule
Approved
Unknown
Unknown
Neoplasms; Thyroid Neoplasms; Carcinoma, Medullary; Carcinoma, Non-Small-Cell Lung
Coiled-coil domain-containing protein 6/Tyrosine-protein kinase receptor RET inhibitor
PRALSETINIB
×
Maximum Phase:
4
First Approval:
2020
UNII:
1WPE73O1WV
Molecule Type:
Small molecule
Molecular Formula:
C27H32FN9O2
Molecular Weight:
533.61
AlogP:
4.2
PSA:
135.53
HBD:
3.0
HBA:
#RotB:
8.0
Source:
BEMPEDOIC ACID
2020
Small molecule
Approved
Unknown
Unknown
Diabetes Mellitus, Type 2; Hypercholesterolemia; Lipid Metabolism Disorders; Hyperlipidemias; Atherosclerosis; Cardiovascular Diseases; Coronary Artery Disease; Hyperlipoproteinemia Type II
ATP-citrate synthase inhibitor
BEMPEDOIC ACID
×
Maximum Phase:
4
First Approval:
2020
UNII:
1EJ6Z6Q368
Molecule Type:
Small molecule
Molecular Formula:
C19H36O5
Molecular Weight:
344.49
AlogP:
4.47
PSA:
94.83
HBD:
3.0
HBA:
#RotB:
14.0
Source:
RIMEGEPANT
2020
Small molecule
Approved
Unknown
Unknown
Psoriasis; Trigeminal Neuralgia; Migraine Disorders
Calcitonin gene-related peptide type 1 receptor antagonist
RIMEGEPANT
×
Maximum Phase:
4
First Approval:
2020
UNII:
997WVV895X
Molecule Type:
Small molecule
Molecular Formula:
C28H28F2N6O3
Molecular Weight:
534.57
AlogP:
4.49
PSA:
119.13
HBD:
2.0
HBA:
#RotB:
3.0
Source:
BEROTRALSTAT
2020
Small molecule
Approved
Unknown
Unknown
Angioedemas, Hereditary
Unknown
BEROTRALSTAT
×
Maximum Phase:
4
First Approval:
2020
UNII:
XZA0KB1BDQ
Molecule Type:
Small molecule
Molecular Formula:
C30H26F4N6O
Molecular Weight:
562.57
AlogP:
5.7
PSA:
108.76
HBD:
3.0
HBA:
#RotB:
9.0
Source:
ARTESUNATE
2020
Small molecule
Approved
Unknown
Unknown
Breast Neoplasms; Carcinoma, Hepatocellular; Friedreich Ataxia; Neoplasms; Colorectal Neoplasms; Crohn Disease; Severe Acute Respiratory Syndrome; Cytomegalovirus Infections; Fever; Malaria, Falciparum; Malaria, Vivax; Schistosomiasis; Schistosomiasis haematobia; Malaria
Unknown
ARTESUNATE
×
Maximum Phase:
4
First Approval:
2020
UNII:
60W3249T9M
Molecule Type:
Small molecule
Molecular Formula:
C19H28O8
Molecular Weight:
384.43
AlogP:
2.6
PSA:
100.52
HBD:
1.0
HBA:
#RotB:
4.0
Source:
REMIMAZOLAM BESYLATE
2020
Small molecule
Approved
Unknown
Unknown
Pain
GABA-A receptor; anion channel positive allosteric modulator
REMIMAZOLAM BESYLATE
×
Maximum Phase:
4
First Approval:
2020
UNII:
280XQ6482H
Molecule Type:
Small molecule
Molecular Formula:
C27H25BrN4O5S
Molecular Weight:
597.49
AlogP:
4.18
PSA:
69.37
HBD:
0.0
HBA:
#RotB:
4.0
Source:
FLORTAUCIPIR
2020
Small molecule
Approved
Unknown
Unknown
Alzheimer Disease
Unknown
FLORTAUCIPIR
×
Maximum Phase:
4
First Approval:
2020
UNII:
J09QS3Z3WB
Molecule Type:
Small molecule
Molecular Formula:
C16H10FN3
Molecular Weight:
263.28
AlogP:
3.92
PSA:
41.57
HBD:
1.0
HBA:
#RotB:
1.0
Source:
AVAPRITINIB
2020
Small molecule
Approved
Unknown
Unknown
Glioma; Leukemia, Mast-Cell; Mastocytosis, Systemic; Gastrointestinal Stromal Tumors; Neoplasms
Platelet-derived growth factor receptor alpha inhibitor
AVAPRITINIB
×
Maximum Phase:
4
First Approval:
2020
UNII:
513P80B4YJ
Molecule Type:
Small molecule
Molecular Formula:
C26H27FN10
Molecular Weight:
498.57
AlogP:
2.61
PSA:
106.29
HBD:
1.0
HBA:
#RotB:
5.0
Source:
REMDESIVIR
2020
Small molecule
Approved
Unknown
Unknown
Pneumonia, Viral; Hemorrhagic Fever, Ebola; Respiratory Distress Syndrome; Severe Acute Respiratory Syndrome
Replicase polyprotein 1ab inhibitor
REMDESIVIR
×
Maximum Phase:
4
First Approval:
2020
UNII:
3QKI37EEHE
Molecule Type:
Small molecule
Molecular Formula:
C27H35N6O8P
Molecular Weight:
602.59
AlogP:
2.31
PSA:
203.55
HBD:
4.0
HBA:
#RotB:
13.0
Source:
TIRBANIBULIN
2020
Small molecule
Approved
Unknown
Unknown
Leukemia, Myeloid, Acute; Lymphoma; Prostatic Neoplasms, Castration-Resistant; Keratosis, Actinic
Tyrosine-protein kinase SRC inhibitor
TIRBANIBULIN
×
Maximum Phase:
4
First Approval:
2020
UNII:
4V9848RS5G
Molecule Type:
Small molecule
Molecular Formula:
C26H29N3O3
Molecular Weight:
431.54
AlogP:
3.32
PSA:
63.69
HBD:
1.0
HBA:
#RotB:
9.0
Source:
OLICERIDINE
2020
Small molecule
Approved
Unknown
Unknown
Pain; Acute Pain
Mu opioid receptor agonist
OLICERIDINE
×
Maximum Phase:
4
First Approval:
2020
UNII:
MCN858TCP0
Molecule Type:
Small molecule
Molecular Formula:
C22H30N2O2S
Molecular Weight:
386.56
AlogP:
4.69
PSA:
43.38
HBD:
1.0
HBA:
#RotB:
7.0
Source:
RIPRETINIB
2020
Small molecule
Approved
Unknown
Unknown
Gastrointestinal Stromal Tumors; Neoplasms
Platelet-derived growth factor receptor alpha inhibitor
RIPRETINIB
×
Maximum Phase:
4
First Approval:
2020
UNII:
9XW757O13D
Molecule Type:
Small molecule
Molecular Formula:
C24H21BrFN5O2
Molecular Weight:
510.37
AlogP:
5.67
PSA:
88.05
HBD:
3.0
HBA:
#RotB:
5.0
Source:
MONOMETHYL FUMARATE
2020
Small molecule
Approved
Unknown
ORAL
Multiple Sclerosis, Relapsing-Remitting; Multiple Sclerosis
Kelch-like ECH-associated protein 1 inhibitor
MONOMETHYL FUMARATE
×
Maximum Phase:
4
First Approval:
2020
UNII:
45IUB1PX8R
Molecule Type:
Small molecule
Molecular Formula:
C5H6O4
Molecular Weight:
130.1
AlogP:
-0.2
PSA:
63.6
HBD:
1.0
HBA:
#RotB:
2.0
Source:
BEROTRALSTAT HYDROCHLORIDE
2020
Small molecule
Unknown
Unknown
Unknown
Angioedemas, Hereditary
Plasma kallikrein inhibitor
BEROTRALSTAT HYDROCHLORIDE
×
Maximum Phase:
4
First Approval:
2020
UNII:
88SH1NBL2B
Molecule Type:
Small molecule
Molecular Formula:
C30H28Cl2F4N6O
Molecular Weight:
635.49
AlogP:
5.7
PSA:
108.76
HBD:
3.0
HBA:
#RotB:
9.0
Source:
LURBINECTEDIN
2020
Small molecule
Approved
Unknown
Unknown
Carcinoid Tumor; Endometrial Neoplasms; Glioblastoma; Leukemia; Stomach Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Mesothelioma; Sarcoma; Ovarian Neoplasms; Neoplasms; Small Cell Lung Carcinoma
DNA negative modulator
LURBINECTEDIN
×
Maximum Phase:
4
First Approval:
2020
UNII:
2CN60TN6ZS
Molecule Type:
Small molecule
Molecular Formula:
C41H44N4O10S
Molecular Weight:
784.89
AlogP:
4.19
PSA:
164.28
HBD:
4.0
HBA:
#RotB:
3.0
Source:
REMIMAZOLAM
2020
Small molecule
Unknown
Unknown
Unknown
Liver Diseases; Substance-Related Disorders; Precursor Cell Lymphoblastic Leukemia-Lymphoma
Unknown
REMIMAZOLAM
×
Maximum Phase:
4
First Approval:
2020
UNII:
7V4A8U16MB
Molecule Type:
Small molecule
Molecular Formula:
C21H19BrN4O2
Molecular Weight:
439.31
AlogP:
4.18
PSA:
69.37
HBD:
0.0
HBA:
#RotB:
4.0
Source:
MAGNESIUM OXYBATE
2020
Small molecule
Approved
Unknown
Unknown
Unknown
GABA-B receptor agonist
MAGNESIUM OXYBATE
×
Maximum Phase:
4
First Approval:
2020
UNII:
G983HLV265
Molecule Type:
Small molecule
Molecular Formula:
C8H14MgO6
Molecular Weight:
230.5
AlogP:
-0.16
PSA:
57.53
HBD:
2.0
HBA:
#RotB:
3.0
Source:
CALCIUM OXYBATE
2020
Small molecule
Approved
Unknown
Unknown
Unknown
GABA-B receptor agonist
CALCIUM OXYBATE
×
Maximum Phase:
4
First Approval:
2020
UNII:
8W24SYD6ZI
Molecule Type:
Small molecule
Molecular Formula:
C8H14CaO6
Molecular Weight:
246.27
AlogP:
-0.16
PSA:
57.53
HBD:
2.0
HBA:
#RotB:
3.0
Source:
LASMIDITAN
2020
Small molecule
Approved
Unknown
ORAL
Substance-Related Disorders; Migraine Disorders
Serotonin 1f (5-HT1f) receptor agonist
LASMIDITAN
×
Maximum Phase:
4
First Approval:
2020
UNII:
760I9WM792
Molecule Type:
Small molecule
Molecular Formula:
C19H18F3N3O2
Molecular Weight:
377.37
AlogP:
3.28
PSA:
62.3
HBD:
1.0
HBA:
#RotB:
4.0
Source:
SELPERCATINIB
2020
Small molecule
Unknown
Unknown
Unknown
Carcinoma, Medullary; Carcinoma, Non-Small-Cell Lung; Thyroid Neoplasms
Coiled-coil domain-containing protein 6/Tyrosine-protein kinase receptor RET inhibitor
SELPERCATINIB
×
Maximum Phase:
4
First Approval:
2020
UNII:
CEGM9YBNGD
Molecule Type:
Small molecule
Molecular Formula:
C29H31N7O3
Molecular Weight:
525.61
AlogP:
3.28
PSA:
112.04
HBD:
1.0
HBA:
#RotB:
8.0
Source:
RELUGOLIX
2020
Small molecule
Approved
Unknown
Unknown
Endometriosis; Leiomyoma; Pain; Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms
Gonadotropin-releasing hormone receptor antagonist
RELUGOLIX
×
Maximum Phase:
4
First Approval:
2020
UNII:
P76B05O5V6
Molecule Type:
Small molecule
Molecular Formula:
C29H27F2N7O5S
Molecular Weight:
623.64
AlogP:
3.75
PSA:
132.61
HBD:
2.0
HBA:
#RotB:
9.0
Source:
OZANIMOD HYDROCHLORIDE
2020
Small molecule
Approved
Unknown
Unknown
Multiple Sclerosis
Sphingosine 1-phosphate receptor Edg-1 modulator
OZANIMOD HYDROCHLORIDE
×
Maximum Phase:
4
First Approval:
2020
UNII:
3UPR33JAAM
Molecule Type:
Small molecule
Molecular Formula:
C23H25ClN4O3
Molecular Weight:
440.93
AlogP:
3.63
PSA:
104.2
HBD:
2.0
HBA:
#RotB:
7.0
Source:
RISDIPLAM
2020
Small molecule
Approved
Unknown
Unknown
Atrophy; Muscular Atrophy, Spinal
SMN2 pre-mRNA positive modulator
RISDIPLAM
×
Maximum Phase:
4
First Approval:
2020
UNII:
76RS4S2ET1
Molecule Type:
Small molecule
Molecular Formula:
C22H23N7O
Molecular Weight:
401.47
AlogP:
1.96
PSA:
79.83
HBD:
1.0
HBA:
#RotB:
2.0
Source:
PEMIGATINIB
2020
Small molecule
Approved
Unknown
Unknown
Leukemia, Myeloid, Acute; Endometrial Neoplasms; Myeloproliferative Disorders; Urinary Bladder Neoplasms; Urogenital Neoplasms; Cholangiocarcinoma; Neoplasms
Fibroblast growth factor receptor 1 inhibitor
PEMIGATINIB
×
Maximum Phase:
4
First Approval:
2020
UNII:
Y6BX7BL23K
Molecule Type:
Small molecule
Molecular Formula:
C24H27F2N5O4
Molecular Weight:
487.51
AlogP:
3.66
PSA:
83.16
HBD:
1.0
HBA:
#RotB:
6.0
Source:
TAZEMETOSTAT HYDROBROMIDE
2020
Small molecule
Approved
Unknown
Unknown
Lymphoma, Follicular; Sarcoma
Histone-lysine N-methyltransferase EZH2 inhibitor
TAZEMETOSTAT HYDROBROMIDE
×
Maximum Phase:
4
First Approval:
2020
UNII:
6P89T5M073
Molecule Type:
Small molecule
Molecular Formula:
C34H45BrN4O4
Molecular Weight:
653.66
AlogP:
4.73
PSA:
86.9
HBD:
2.0
HBA:
#RotB:
9.0
Source:
FLUOROESTRADIOL
2020
Small molecule
Approved
Unknown
Unknown
Unknown
Unknown
FLUOROESTRADIOL
×
Maximum Phase:
4
First Approval:
2020
UNII:
LVI5P34A3C
Molecule Type:
Small molecule
Molecular Formula:
C18H23FO2
Molecular Weight:
290.38
AlogP:
3.56
PSA:
40.46
HBD:
2.0
HBA:
#RotB:
0.0
Source:
OSILODROSTAT PHOSPHATE
2020
Small molecule
Approved
Unknown
Unknown
Pituitary ACTH Hypersecretion
Cytochrome P450 11B1 inhibitor
OSILODROSTAT PHOSPHATE
×
Maximum Phase:
4
First Approval:
2020
UNII:
Y6581YAW9V
Molecule Type:
Small molecule
Molecular Formula:
C13H13FN3O4P
Molecular Weight:
325.24
AlogP:
2.43
PSA:
41.61
HBD:
0.0
HBA:
#RotB:
1.0
Source:
POTASSIUM BITARTRATE
2020
Small molecule
Approved
Unknown
Unknown
Unknown
Unknown
POTASSIUM BITARTRATE
×
Maximum Phase:
4
First Approval:
2020
UNII:
NPT6P8P3UU
Molecule Type:
Small molecule
Molecular Formula:
C4H5KO6
Molecular Weight:
188.18
AlogP:
None
PSA:
None
HBD:
None
HBA:
#RotB:
None
Source:
NIFURTIMOX
2020
Small molecule
Approved
Unknown
Unknown
Neuroblastoma; Trypanosomiasis, African; Chagas Disease; Leishmaniasis; Trypanosomiasis
DNA inhibitor
NIFURTIMOX
×
Maximum Phase:
4
First Approval:
2020
UNII:
M84I3K7C2O
Molecule Type:
Small molecule
Molecular Formula:
C10H13N3O5S
Molecular Weight:
287.3
AlogP:
0.64
PSA:
106.02
HBD:
0.0
HBA:
#RotB:
3.0
Source:
POTASSIUM OXYBATE
2020
Small molecule
Approved
Unknown
Unknown
Unknown
GABA-B receptor agonist
POTASSIUM OXYBATE
×
Maximum Phase:
4
First Approval:
2020
UNII:
S8NKF3H3KT
Molecule Type:
Small molecule
Molecular Formula:
C4H7KO3
Molecular Weight:
142.19
AlogP:
-0.16
PSA:
57.53
HBD:
2.0
HBA:
#RotB:
3.0
Source:
FLUOROESTRADIOL F-18
2020
Small molecule
Approved
Unknown
Unknown
Breast Neoplasms
Diagnostic agent
FLUOROESTRADIOL F-18
×
Maximum Phase:
4
First Approval:
2020
UNII:
T32277KB09
Molecule Type:
Small molecule
Molecular Formula:
C18H23FO2
Molecular Weight:
289.38
AlogP:
3.56
PSA:
40.46
HBD:
2.0
HBA:
#RotB:
0.0
Source:
FOSTEMSAVIR TROMETHAMINE
2020
Small molecule
Approved
Unknown
Unknown
Autoimmune Diseases; HIV Infections
Envelope polyprotein GP160 inhibitor
FOSTEMSAVIR TROMETHAMINE
×
Maximum Phase:
4
First Approval:
2020
UNII:
2X513P36U0
Molecule Type:
Small molecule
Molecular Formula:
C29H37N8O11P
Molecular Weight:
704.63
AlogP:
1.17
PSA:
182.21
HBD:
2.0
HBA:
#RotB:
8.0
Source:
CAPMATINIB
2020
Small molecule
Approved
Unknown
Unknown
Breast Neoplasms; Glioblastoma; Liver Diseases; Carcinoma, Hepatocellular; Kidney Neoplasms; Lung Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung; Sarcoma; Neoplasms
Hepatocyte growth factor receptor inhibitor
CAPMATINIB
×
Maximum Phase:
4
First Approval:
2020
UNII:
TY34L4F9OZ
Molecule Type:
Small molecule
Molecular Formula:
C23H17FN6O
Molecular Weight:
412.43
AlogP:
3.43
PSA:
85.07
HBD:
1.0
HBA:
#RotB:
4.0
Source:
TAZEMETOSTAT
2020
Small molecule
Approved
Unknown
Unknown
Carcinoma, Squamous Cell; Lymphoma; Lymphoma, Large B-Cell, Diffuse; Prostatic Neoplasms; Urinary Bladder Neoplasms; Mesothelioma; Lymphoma, Follicular; Sarcoma
Unknown
TAZEMETOSTAT
×
Maximum Phase:
4
First Approval:
2020
UNII:
Q40W93WPE1
Molecule Type:
Small molecule
Molecular Formula:
C34H44N4O4
Molecular Weight:
572.75
AlogP:
4.73
PSA:
86.9
HBD:
2.0
HBA:
#RotB:
9.0
Source:
1
2
…
53
54
55
56
57
58
59
…
186
187
Next »
Download Option
Close
Header
Compound Name
Maximum Phase
Compound Structure
Smile
Inchi
InchiKey
Compound Properties
Molecular Formula
Molecular Weight
ALogP
PSA